Humacyte Sees Unusually Large Options Volume (NASDAQ:HUMA)

Posted by Stanley Muller on Jun 11th, 2026

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) saw unusually large options trading activity on Thursday. Traders acquired 4,104 call options on the company. This represents an increase of approximately 152% compared to the average volume of 1,627 call options.

Insider Activity at Humacyte

In other Humacyte news, insider Shamik J. Parikh sold 45,887 shares of Humacyte stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the transaction, the insider directly owned 272,713 shares of the company’s stock, valued at $245,441.70. The trade was a 14.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius acquired 56,818 shares of Humacyte stock in a transaction on Tuesday, May 19th. The stock was purchased at an average cost of $0.88 per share, with a total value of $49,999.84. Following the completion of the transaction, the director directly owned 148,025 shares in the company, valued at $130,262. This represents a 62.30% increase in their position. The disclosure for this purchase is available in the SEC filing. 3.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in HUMA. R Squared Ltd purchased a new position in shares of Humacyte in the fourth quarter worth about $25,000. Atom Investors LP bought a new position in Humacyte during the 4th quarter worth approximately $25,000. Truist Financial Corp purchased a new position in Humacyte in the 3rd quarter worth approximately $28,000. Prudential Financial Inc. bought a new stake in Humacyte in the second quarter valued at approximately $28,000. Finally, Financial Advisors Network Inc. bought a new stake in Humacyte in the second quarter valued at approximately $28,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Analyst Upgrades and Downgrades

HUMA has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Friday, April 10th. Benchmark upped their price objective on Humacyte to $2.00 and gave the company a “speculative buy” rating in a research note on Monday, June 1st. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Tuesday, April 28th. BTIG Research restated a “buy” rating and issued a $2.00 target price on shares of Humacyte in a research note on Monday. Finally, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective (up from $3.00) on shares of Humacyte in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.57.

Get Our Latest Stock Report on HUMA

Humacyte Price Performance

Shares of HUMA stock traded down $0.29 during trading on Thursday, hitting $1.06. The company had a trading volume of 17,613,344 shares, compared to its average volume of 6,673,518. The stock’s 50-day moving average is $0.93 and its two-hundred day moving average is $1.04. The stock has a market capitalization of $234.23 million, a price-to-earnings ratio of -1.85 and a beta of 2.45. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. Humacyte has a 52 week low of $0.55 and a 52 week high of $2.84.

Humacyte (NASDAQ:HUMA – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.46 million. As a group, analysts predict that Humacyte will post -0.32 EPS for the current fiscal year.

About Humacyte

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.